Clinical trial
Imatinib Mesylate in Treating Patients With Recurrent or Persistent Uterine…
NCT00075400 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00075400 |
|---|---|
| Title | Imatinib Mesylate in Treating Patients With Recurrent or Persistent Uterine Cancer |
| Official title | A Phase II Evaluation of Gleevec(TM) (NCI-Supplied Agent: STI571 [Imatinib Mesylate], NSC# 716051) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Collaborators | Gynecologic Oncology Group |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Recurrent Uterine Sarcoma, Uterine Carcinosarcoma |
| Intervention type | Drug, Other |
| Interventions | imatinib mesylate, laboratory biomarker analysis |
| Enrollment | 26 |
| Start date | Jan 1, 2004 |
| Primary completion | Jul 1, 2010 |
| Completion | Jul 1, 2010 |
| First posted | Jan 12, 2004 |
| Last update posted | Jul 24, 2019 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: